Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
about
PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways.The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammationExogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytesThe induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.Interferon alpha and T-cell responses in chronic myeloid leukemia.Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.A tale of two histiocytic disordersDevelopment and dynamics of robust T-cell responses to CML under imatinib treatmentSignaling of c-kit in dendritic cells influences adaptive immunity.Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophagesImatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumorsSrc-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia.Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlationsThe effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.Role of tyrosine kinase inhibitors in tumor immunology.Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis TherapyPlatelet-derived growth factor, transforming growth factor-beta, and connective tissue growth factor in a porcine bronchial model of obliterative bronchiolitis.RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.Reactivation of chronic hepatitis B infection related to imatinib mesylate therapyAlterations of oncogenes expression in NK cells in patients with cancer.Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.Patients with IgA nephropathy exhibit high systemic PDGF-DD levels.Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.Treatment of cockroach allergen asthma model with imatinib attenuates airway responses.Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients.Autocrine signaling of platelet-derived growth factor regulates disabled-2 expression during megakaryocytic differentiation of K562 cells.Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.A case of xanthoma disseminatum treated with imatinib mesylate.In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
P2860
Q33644438-165F69E8-A49F-4BA2-8251-02F8D617FFA5Q33735212-FD38A1B8-D25E-4BD4-A8AC-D0C450B90041Q34015306-9E7D06C7-D422-4566-84D6-93EF883C67ADQ34015801-7315B328-258F-4570-A4CE-4F4806CF8D02Q34983782-18151418-5450-4785-A67E-E336FED84C26Q35898395-E46850EE-B936-42ED-9662-0BF4C418BDADQ35994924-3076FEFC-45CF-4A42-9A7A-3E06B6284779Q36164524-5E50CACB-06D3-4E87-A074-62D5FFB7A29AQ36194635-2A7A4CF5-CE55-4CE5-BD07-6899C66B693CQ36565617-9F7F9EF4-1C96-4FBC-BB70-17D3B1CA082BQ36677315-ED08438D-D523-447B-B6A6-B571AD4EFA50Q36811035-38A13848-8208-48FE-A6F7-80FF099AFEF2Q36934732-A1CA635B-0267-4D56-820A-2BB158551EAAQ36965879-8A62AF9F-5DF4-4248-B4CB-E0AA8428A3E7Q37098840-2C0183E0-447E-4294-954E-AAFB9B526C57Q37288036-B5133EC6-F22E-41CB-8549-FCF4CDA61E00Q37326191-DD13FE9B-6D54-4CB5-B658-36F05A958E06Q37426727-35421DA2-D75D-42D0-9232-965ED3F422ECQ37428671-4954B169-507F-4E01-BB94-AFABE0169C60Q37625756-565723C0-38C3-412D-9D69-9493C7FD5B8CQ37822748-692EE6D0-354E-4EF0-A18F-7D4D1096E249Q37842326-7F1A15B0-D38A-4C67-9A0C-EC75A426D5C6Q37847137-88DA5933-7BFB-4198-B7FE-58047AD8FAC4Q38258904-A53C0D03-F4B3-4E35-88A1-BBC9E4185706Q38261946-E57CDEBA-1E16-4A7E-AD2E-C046C5737E12Q38299218-1553A00F-7AA5-4D51-A83C-89A19CCE9C69Q39718113-8D9D7752-1633-413A-B4D2-73EB603B0898Q41673629-3575D5FD-51FF-4865-A2D6-812C3F404331Q41892625-CD48A7DD-8C6E-445D-8122-EAA201626E7DQ44717067-18C072D3-7AE4-4706-931C-5D12243741E4Q44931488-CF10C774-2654-45C9-94EB-F014EC37A19AQ44957188-7D8D08BE-0B7B-4431-B427-D2FEAB5D6D0EQ45041464-D3193552-98F3-410C-8377-957CEB25308DQ45063930-BE8BCDA8-8AD8-4A90-89F4-E39B1C0950C6Q45281008-C40EA892-215D-4F7C-AFDC-E8FEBFCF063BQ46629748-5A165F2C-71BD-40CE-8F0B-5B1241489819Q46799041-2395C432-F850-4621-843F-FC99E40183BFQ46859831-FB0901EF-DDF6-49BC-A0BE-A6F9D0440D12Q48286590-7A4D800D-F5C8-4409-9C45-55943FD9F196Q48549224-1DAB0C3F-1CB1-4223-BB33-180FA0B797A1
P2860
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Imatinib mesylate affects the ...... pheral blood progenitor cells.
@en
Imatinib mesylate affects the ...... pheral blood progenitor cells.
@nl
type
label
Imatinib mesylate affects the ...... pheral blood progenitor cells.
@en
Imatinib mesylate affects the ...... pheral blood progenitor cells.
@nl
prefLabel
Imatinib mesylate affects the ...... pheral blood progenitor cells.
@en
Imatinib mesylate affects the ...... pheral blood progenitor cells.
@nl
P2093
P1433
P1476
Imatinib mesylate affects the ...... ipheral blood progenitor cells
@en
P2093
Andreas M Boehmler
Anette Rupf
Frank Grünebach
Lothar Kanz
Markus M Weck
Martin R Müller
Peter Brossart
Tim H Brümmendorf
Ulrike Hartmann
Volker L Reichardt
P304
P356
10.1182/BLOOD-2003-03-0975
P407
P50
P577
2003-09-22T00:00:00Z